Appraising the European randomized study of screening for prostate cancer: what do the results mean?
The value of screening for prostate cancer has been a contentious issue within the medical literature for several decades. At the crux of the matter lies a judgment call of whether the potential benefits of screening, a reduction in prostate cancer and all-cause mortality, outweigh the limitations,...
Main Author: | Dragan Ilic |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2015-04-01
|
Series: | Asian Journal of Andrology |
Online Access: | http://www.ajandrology.com/article.asp?issn=1008-682X;year=2015;volume=17;issue=2;spage=221;epage=222;aulast=Ilic |
Similar Items
-
Screening for prostate cancer: what are the benefits ?
by: Murad Lesmana
Published: (2015-12-01) -
Prostate-Specific Antigen fluctuation: what does it mean in diagnosis of prostate cancer?
by: Jun Seok Kim, et al.
Published: (2015-04-01) -
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
by: Scardino Peter T, et al.
Published: (2008-07-01) -
Prostate Cancer Screening in Jamaica: Results of the Largest National Screening Clinic
by: Belinda F. Morrison, et al.
Published: (2016-01-01) -
Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer
by: Pete T. T. Kinnunen, et al.
Published: (2017-08-01)